Register for April's CTN Annual Steering Committee Meeting! |
SHARE ISSUE ON |
|
|
The National Drug Abuse Treatment Clinical Trials Network will hold its Annual Steering Committee Meeting virtually on April 26-28, 2021. The meeting will provide a forum for knowledge exchange of current substance use disorder treatment research findings and their policy implications. Topics will include updates on best practices in the science of addiction and substance use disorders.
Who should attend? Members of the CTN; substance use disorder treatment providers, researchers, and policy makers; as well as those in related fields who share an interest in improving substance use disorder treatment and advancing the science of addiction.
Registration is now open! (Registration closes on Monday, April 12, 2021.)
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Learn More About NIDA's HIV/AIDS Avant Garde Award Program
On April 27 from 1-4:30 pm, the NIDA AIDS Research Program will be holding a virtual Symposium honoring six recipients of the Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research. Symposium registration is now online. The NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research supports individual scientists of exceptional creativity at all career levels who propose high-impact research that will open new areas of HIV research and/or lead to new avenues for prevention and treatment of HIV among people who use drugs.
The AIDS Research Program has also posted a video of the recent symposium discussion with some of NIDA’s remarkable Avenir Award recipients. NIDA's Avenir Awards are designed to stimulate innovation and potentially transformative research from early stage investigators. Congratulations in advance to all of this year's awardees!
|
CTN Trial Progress
 Randomizations for Active Studies as of the March 10 trial Progress Report.
CTN-0060-A-1 - Enrolled 278
CTN-0069 - Enrolled 757
CTN-0079-A-1 - Enrolled 6
CTN-0080 - Enrolled 36
CTN-0082 - Enrolled 218
CTN-0099 - Enrolled 236
CTN-0099-A-1 - Enrolled 68
|
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
New in the CTN Dissemination Library
Tsui JI, et al. Prevalence and medication treatment of opioid use disorder among primary care patients with hepatitis C and HIV. Journal of General Internal Medicine 2021 (in press).
(CTN-0074)
Traynor SM, et al. Self-efficacy as a mediator of patient navigation interventions to engage persons living with HIV and substance use. Drug and Alcohol Dependence 2021;221:108567. (CTN-0049, CTN-0049-A-1)
de la Cruz AM, et al. Creation of an algorithm for clinical decision support for treatment of opioid use disorder with buprenorphine in primary care. Addiction Science & Clinical Practice 2021;16:12. (CTN-0090)
Shulman M, et al. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA-CTN-0100 “Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD).” Addiction Science & Clinical Practice 2021;16:15. (CTN-0100)
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
News from the Nodes
Northeast
 CTN-0116: Pharmacist-Integrated Collaborative Model of Medication Treatment for Opioid Use Disorder (PharmICO)
The Northeast Node in collaboration with its partners at Penobscot Community Health Center (PCHC) are excited to lead the new CTN-0116 study (PharmICO).
Pharmacists remain an underutilized resource in the treatment of opioid use disorder (OUD). Although studies have engaged pharmacists in dispensing medications in OUD treatment (MOUD), few studies have evaluated collaborative care models in which pharmacists are an active, integral part of a primary care team offering OUD care.
In this Phase 1 project, we seek to leverage a promising model of pharmacist-integrated care for OUD pioneered at PCHC to
- employ a mixed methods approach to evaluate the feasibility and acceptability of implementing a pharmacist-integrated model of MOUD into the clinical workflow of a diverse array of clinical sites and
- evaluate the impact of the pharmacist-integrated model on the clinical sites’ capacity for MOUD care and on patient engagement in OUD care.
Once we complete the development of the protocol, the study will engage four partnering clinic/pharmacy sites. |
New England Consortium
The Substance Abuse and Mental Health Administration (SAMHSA) has released a new resource, Use of Medication-Assisted Treatment in Emergency Departments. This guide examines emerging and best practices for initiating medication treatments for substance use disorder in emergency departments. It also reviews the existing literature and science of the topic, identifies gaps in knowledge and discusses challenges of implementation.
Yale Program in Addiction Medicine Core Faculty members, Drs. Gail D’Onofrio and Kathryn Hawk, provided key leadership in the production of this resource, which notably draws upon important research from Program faculty and collaborators on emergency department-initiated buprenorphine/naloxone treatment as well as national dissemination and impact of this practice.
Pacific Northwest
 ADAI Changes Its Name!
The Pacific Northwest Node (and the CTN Dissemination Library) are both housed at ADAI at the University of Washington. ADAI recently changed its name from the Alcohol & Drug Abuse Institute to the Addictions, Drug & Alcohol Institute (ADAI). Recognizing that stigmatizing language can be a major barrier for seeking and receiving medical or behavioral health care, particularly for already-marginalized populations, we wanted to remove the term "abuse" from our name. Our new name also better reflects the full scope of the work that is conducted at ADAI around both addiction and non-addiction substance use issues, such as drug overdose, safer use of substances, and our cannabis research program. Read more about this change. |
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
CTN Youth SIG Webinar: Enhancing Primary Care-Based Treatment for OUD (March 26)
March 26, 2021, 10:00am - 12:00pm (ET)
 In this CTN Youth SIG webinar, Dr. Hadland will discuss common facilitators and barriers to receipt of addiction treatment from the perspective of clinicians, youth, and family members. He will also describe approaches to improving clinical services for youth with OUD and will discuss quantifying receipt of addiction treatment and retention in care among youth with opioid use disorder (OUD).
Dr. Scott Hadland is a pediatrician and addiction specialist at Boston Medical Center and Boston University School of Medicine. He holds triple board certification in General Pediatrics, Adolescent Medicine, and Addiction Medicine. Dr. Hadland’s clinical and research interests focus on adolescent and young adult substance use disorder prevention and treatment, and on improving care for youth and families affected by substance use.
Friday, March 26, 2021 (11:00 a.m. - 12:00 p.m. ET)
Join Zoom Meeting: https://dartmouth.zoom.us/j/98461113542?pwd=Zk1sOHNDS1IwVDhkc3BFWlM2TVJOQT09
Zoom Meeting ID: 984 6111 3542
Passcode: 566856
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
Also of Interest
Position Opening: Postdoc Fellowship in Behavioral Health Dissemination & Implementation Research (Stanford Med School)
The Stanford University School of Medicine Center for Behavioral Health Services and Implementation Research (CBHSIR) invites applicants for a postdoctoral fellowship in mental health and addiction treatment dissemination & implementation (D&I) research. Applications are being accepted now for a Spring/Summer 2021 start.
For more information, or to apply, email cover letter, CV, and writing sample(s) to: Dr. Mark McGovern, Stanford University School of Medicine: mpmcg@stanford.edu.
Learn more here.
Coming in April: NIH FOA for Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities
The National Institute on Minority Health and Health Disparities (NIMHD), with other NIH Institutes, Centers and Offices (ICOs), intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications on (1) observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, and (2) intervention research that addresses SRD in order to improve minority health or reduce health disparities.
The FOA, which will use the R01 activity code, is expected to be published in April 2021 with an expected application due date in August 2021.
More information here.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
From the ATTC Network
ATTC Messenger - March 2021
An Evaluation of Recovery Housing in Missouri:
Key Outcomes and Recommendations. By Claire Wood, PhD; Brenna Lohmann, MSW; Kori Richardson, MPP; Alex Duello, MPH; Marsha Hourd; Rosie Anderson-Harper, MA; and Rachel Winograd, PhD.
ATTC/NIATx Service Improvement Blog
Is the term "marijuana" racist? - Deena Murphy, Opioid Response Network STR-TA Consortium
Change Project 911: Help! My Change Team has lost its energy - Mat Roosa, LCSW-R |
Upcoming Events
April 10-14, 2021: AATOD 2021 Conference (virtual)
Theme: Forging Partnerships to Improve Access to Quality Care
Registration is open! 
April 26-28, 2021: Annual CTN Steering Committee Meeting
Registration now open!
June 21-24, 2021: CPDD 2021 Annual Meeting (virtual)
Registration is open!
|
   
|
